{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:21:28Z","timestamp":1776900088295,"version":"3.51.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U01AG029824"],"award-info":[{"award-number":["U01AG029824"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute","award":["U19AG062682"],"award-info":[{"award-number":["U19AG062682"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["334047"],"award-info":[{"award-number":["334047"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Health and Medical Research Institute","award":["1127060"],"award-info":[{"award-number":["1127060"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["1171422"],"award-info":[{"award-number":["1171422"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["R35 CA253185"],"award-info":[{"award-number":["R35 CA253185"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>For the design and analysis of clinical trials with time-to-event outcomes, the Cox proportional hazards model and the logrank test have been the cornerstone methods for many decades. Increasingly, the key assumption of proportionality\u2014or time-fixed effects\u2014that underpins these methods has been called into question. The availability of novel therapies with new mechanisms of action and clinical trials of longer duration mean that non-proportional hazards are now more frequently encountered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We compared several regression-based methods to model time-dependent treatment effects. For illustration purposes, we used selected endpoints from a large, community-based clinical trial of low dose daily aspirin in older persons. Relative and absolute estimands were defined, and analyses were conducted in all participants. Additional exploratory analyses were undertaken by selected subgroups of interest using interaction terms in the regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In the trial with median 4.7 years follow-up, we found evidence for non-proportionality and a time-dependent treatment effect of aspirin on cancer mortality not previously reported in trial findings. We also found some evidence of time-dependence to an aspirin by age interaction for major adverse cardiovascular events. For other endpoints, time-fixed treatment effect estimates were confirmed as appropriate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The consideration of treatment effects using both absolute and relative estimands enhanced clinical insights into potential dynamic treatment effects. We recommend these analytical approaches as an adjunct to primary analyses to fully explore findings from clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13063-022-06803-x","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:03:04Z","timestamp":1665054184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Examining evidence of time-dependent treatment effects: an illustration using regression methods"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2550-9674","authenticated-orcid":false,"given":"Kim M.","family":"Jachno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Heritier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn L.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Mahady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"2","key":"6803_CR1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodol. 1972;34(2):187\u2013220.","journal-title":"J R Stat Soc Ser B Methodol."},{"issue":"15","key":"6803_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1200\/jco.2015.64.2488","volume":"34","author":"L Trinquart","year":"2016","unstructured":"Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. J Clin Oncol. 2016;34(15):1813\u20139. https:\/\/doi.org\/10.1200\/jco.2015.64.2488.","journal-title":"J Clin Oncol."},{"issue":"15\u2013suppl","key":"6803_CR3","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1200\/JCO.2018.36.15-suppl.2543","volume":"36","author":"R Rahman","year":"2018","unstructured":"Rahman R, Fell G, Trippa L, Alexander BM. Violations of the proportional hazards assumption in randomized phase III oncology clinical trials. J Clin Oncol. 2018;36(15\u2013suppl):2543\u201343. https:\/\/doi.org\/10.1200\/JCO.2018.36.15-suppl.2543.","journal-title":"J Clin Oncol."},{"issue":"2","key":"6803_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/bjc.1995.364","volume":"72","author":"DG Altman","year":"1995","unstructured":"Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72(2):511\u20138.","journal-title":"Br J Cancer."},{"issue":"22","key":"6803_CR5","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1200\/jco.2007.14.1192","volume":"26","author":"S Mathoulin-Pelissier","year":"2008","unstructured":"Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol. 2008;26(22):3721\u20136. https:\/\/doi.org\/10.1200\/jco.2007.14.1192.","journal-title":"J Clin Oncol."},{"issue":"1","key":"6803_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12874-019-0749-1","volume":"19","author":"K Jachno","year":"2019","unstructured":"Jachno K, Heritier S, Wolfe R. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice. BMC Med Res Methodol. 2019;19(1):103. https:\/\/doi.org\/10.1186\/s12874-019-0749-1.","journal-title":"BMC Med Res Methodol."},{"issue":"15","key":"6803_CR7","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175\u201397. https:\/\/doi.org\/10.1002\/sim.1203.","journal-title":"Stat Med."},{"issue":"1","key":"6803_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13(1):152. https:\/\/doi.org\/10.1186\/1471-2288-13-152.","journal-title":"BMC Med Res Methodol."},{"issue":"1","key":"6803_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/biom.12384","volume":"72","author":"L Zhao","year":"2016","unstructured":"Zhao L, Claggett B, Tian L, Uno H, Pfeffer MA, Solomon SD, et al. On the restricted mean survival time curve in survival analysis. Biometrics. 2016;72(1):215\u201321. https:\/\/doi.org\/10.1111\/biom.12384.","journal-title":"Biometrics."},{"issue":"4","key":"6803_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/00949655.2013.845890","volume":"85","author":"MJ Rutherford","year":"2015","unstructured":"Rutherford MJ, Crowther MJ, Lambert PC. The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study. J Stat Comput Simul. 2015;85(4):777\u201393. https:\/\/doi.org\/10.1080\/00949655.2013.845890.","journal-title":"J Stat Comput Simul."},{"key":"6803_CR11","volume-title":"Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model","author":"P Royston","year":"2011","unstructured":"Royston P, Lambert PC. Flexible parametric survival analysis using Stata: beyond the Cox model. College Station: Stata Press; 2011."},{"issue":"23","key":"6803_CR12","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1002\/sim.5823","volume":"32","author":"MJ Crowther","year":"2013","unstructured":"Crowther MJ, Lambert PC. Simulating biologically plausible complex survival data. Stat Med. 2013;32(23):4118\u201334. https:\/\/doi.org\/10.1002\/sim.5823.","journal-title":"Stat Med."},{"issue":"1","key":"6803_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/0962280209105020","volume":"19","author":"PK Andersen","year":"2010","unstructured":"Andersen PK, Pohar Perme M. Pseudo-observations in survival analysis. Stat Methods Med Res. 2010;19(1):71\u201399. https:\/\/doi.org\/10.1177\/0962280209105020.","journal-title":"Stat Methods Med Res."},{"issue":"3","key":"6803_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/1536867x1501500313","volume":"15","author":"M Overgaard","year":"2015","unstructured":"Overgaard M, Andersen PK, Parner ET. Regression analysis of censored data using pseudo-observations: an update. Stata J. 2015;15(3):809\u201321. https:\/\/doi.org\/10.1177\/1536867x1501500313.","journal-title":"Stata J."},{"key":"6803_CR15","unstructured":"International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guidelines: Statistical Principles for Clinical Trials E9. London: European Medicines Agency; 1998."},{"key":"6803_CR16","unstructured":"ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Amsterdam: European Medicines Agency; 2020."},{"issue":"6","key":"6803_CR17","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ije\/dyw118","volume":"45","author":"DM Kent","year":"2016","unstructured":"Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. Int J Epidemiol. 2016;45(6):2075\u201388. https:\/\/doi.org\/10.1093\/ije\/dyw118.","journal-title":"Int J Epidemiol."},{"key":"6803_CR18","volume-title":"race-, and ethnicity-specific data in medical device clinical studies","author":"Evaluation and reporting of age-","year":"2014","unstructured":"Evaluation and reporting of age-. race-, and ethnicity-specific data in medical device clinical studies. Maryland: U.S. Food and Drug Administration; 2014."},{"key":"6803_CR19","volume-title":"race-, and ethnicity-specific data in medical device clinical studies","author":"Evaluation and reporting of age-","year":"2017","unstructured":"Evaluation and reporting of age-. race-, and ethnicity-specific data in medical device clinical studies. Maryland: U.S. Food and Drug Administration; 2017."},{"issue":"16","key":"6803_CR20","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMe1812000","volume":"379","author":"PM Ridker","year":"2018","unstructured":"Ridker PM. Should aspirin be used for primary prevention in the post-statin era? N Engl J Med. 2018;379(16):1572\u20134. https:\/\/doi.org\/10.1056\/NEJMe1812000.","journal-title":"N Engl J Med."},{"issue":"3","key":"6803_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jnci\/djaa115","volume":"113","author":"ET Hawk","year":"2021","unstructured":"Hawk ET, Maresso KC. The ASPREE trial: an unanticipated stimulus for greater precision in prevention? J Natl Cancer Inst. 2021;113(3):221\u20132. https:\/\/doi.org\/10.1093\/jnci\/djaa115.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"6803_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1053\/j.gastro.2018.11.063","volume":"156","author":"AT Chan","year":"2019","unstructured":"Chan AT, McNeil J. Aspirin and cancer prevention in the elderly: where do we go from here? Gastroenterology. 2019;156(3):534\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2018.11.063.","journal-title":"Gastroenterology."},{"issue":"1","key":"6803_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2307\/2335876","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239\u201341. https:\/\/doi.org\/10.2307\/2335876.","journal-title":"Biometrika."},{"issue":"3","key":"6803_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2307\/2337123","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515\u201326. https:\/\/doi.org\/10.2307\/2337123.","journal-title":"Biometrika."},{"issue":"3","key":"6803_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/00949655.2017.1397151","volume":"88","author":"PC Austin","year":"2018","unstructured":"Austin PC. Statistical power to detect violation of the proportional hazards assumption when using the Cox regression model. J Stat Comput Simul. 2018;88(3):533\u201352. https:\/\/doi.org\/10.1080\/00949655.2017.1397151.","journal-title":"J Stat Comput Simul."},{"key":"6803_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1536867X0900900206","volume":"9","author":"PC Lambert","year":"2009","unstructured":"Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9:265\u201390. https:\/\/doi.org\/10.1177\/1536867X0900900206.","journal-title":"Stata J."},{"issue":"4","key":"6803_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1177\/1536867x1601600410","volume":"16","author":"H Bower","year":"2016","unstructured":"Bower H, Crowther MJ, Lambert PC. strcs: a command for fitting flexible parametric survival models on the Log-hazard Scale. Stata J. 2016;16(4):989\u20131012. https:\/\/doi.org\/10.1177\/1536867x1601600410.","journal-title":"Stata J."},{"issue":"4","key":"6803_CR28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1177\/1536867X1501500409","volume":"15","author":"P Royston","year":"2015","unstructured":"Royston P. Estimating the treatment effect in a clinical trial using difference in restricted mean survival time. Stata J. 2015;15(4):1098\u2013117. https:\/\/doi.org\/10.1177\/1536867X1501500409.","journal-title":"Stata J."},{"issue":"16","key":"6803_CR29","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379(16):1499\u2013508. https:\/\/doi.org\/10.1056\/NEJMoa1800722.","journal-title":"N Engl J Med."},{"issue":"16","key":"6803_CR30","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1805819.","journal-title":"N Engl J Med."},{"issue":"16","key":"6803_CR31","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1803955.","journal-title":"N Engl J Med."},{"issue":"3","key":"6803_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277\u201387. https:\/\/doi.org\/10.1001\/jama.2018.20578.","journal-title":"JAMA."},{"issue":"9826","key":"6803_CR33","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(11)61720-0.","journal-title":"Lancet."},{"issue":"3","key":"6803_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jnci\/djaa114","volume":"113","author":"JJ McNeil","year":"2020","unstructured":"McNeil JJ, Gibbs P, Orchard SG, Lockery JE, Bernstein WB, Cao Y, et al. Effect of aspirin on cancer incidence and mortality in older adults. J Natl Cancer Inst. 2020;113(3):258\u201365. https:\/\/doi.org\/10.1093\/jnci\/djaa114.","journal-title":"J Natl Cancer Inst."},{"key":"6803_CR35","doi-asserted-by":"publisher","unstructured":"Mahady SE, Margolis KL, Chan A, Polekhina G, Woods RL, Wolfe R, et\u00a0al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut. 2020;2020\u2013321585. https:\/\/doi.org\/10.1136\/gutjnl-2020-321585.","DOI":"10.1136\/gutjnl-2020-321585"},{"issue":"11","key":"6803_CR36","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/sim.6889","volume":"35","author":"T Sit","year":"2016","unstructured":"Sit T, Liu M, Shnaidman M, Ying Z. Design and analysis of clinical trials in the presence of delayed treatment effect. Stat Med. 2016;35(11):1774\u20139. https:\/\/doi.org\/10.1002\/sim.6889.","journal-title":"Stat Med."},{"issue":"30","key":"6803_CR37","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1002\/sim.7937","volume":"37","author":"Z Xu","year":"2018","unstructured":"Xu Z, Park Y, Zhen B, Zhu B. Designing cancer immunotherapy trials with random treatment time-lag effect. Stat Med. 2018;37(30):4589\u2013609. https:\/\/doi.org\/10.1002\/sim.7937.","journal-title":"Stat Med."},{"issue":"4","key":"6803_CR38","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/biom.12916","volume":"74","author":"T Ye","year":"2018","unstructured":"Ye T, Yu M. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect. Biometrics. 2018;74(4):1292\u2013300. https:\/\/doi.org\/10.1111\/biom.12916.","journal-title":"Biometrics."},{"issue":"12","key":"6803_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/pst.1982","volume":"1","author":"J Wu","year":"2019","unstructured":"Wu J, Wei J. Cancer immunotherapy trial design with delayed treatment effect. Pharm Stat. 2019;1(12):202\u201313. https:\/\/doi.org\/10.1002\/pst.1982.","journal-title":"Pharm Stat."},{"issue":"3","key":"6803_CR40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/pst.1923","volume":"18","author":"JL Jim\u00e9nez","year":"2019","unstructured":"Jim\u00e9nez JL, Stalbovskaya V, Jones B. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects. Pharm Stat. 2019;18(3):287\u2013303. https:\/\/doi.org\/10.1002\/pst.1923.","journal-title":"Pharm Stat."},{"key":"6803_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/pst.2062","volume":"20","author":"R Ristl","year":"2020","unstructured":"Ristl R, Ballarini NM, G\u00f6tte H, Sch\u00fcler A, Posch M, K\u00f6nig F. Delayed treatment effects, treatment switching and heterogeneous patient populations: how to design and analyze RCTs in oncology. Pharm Stat. 2020;20:129\u201345. https:\/\/doi.org\/10.1002\/pst.2062.","journal-title":"Pharm Stat."},{"issue":"12","key":"6803_CR42","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.1016\/j.csda.2007.03.006","volume":"51","author":"SH Lee","year":"2007","unstructured":"Lee SH. On the versatility of the combination of the weighted log-rank statistics. Comput Stat Data Anal. 2007;51(12):6557\u201364. https:\/\/doi.org\/10.1016\/j.csda.2007.03.006.","journal-title":"Comput Stat Data Anal."},{"issue":"11","key":"6803_CR43","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/sim.6453","volume":"34","author":"S Yang","year":"2015","unstructured":"Yang S, Prentice RL. Assessing potentially time-dependent treatment effect from clinical trials and observational studies for survival data, with applications to the Women\u2019s Health Initiative combined hormone therapy trial. Stat Med. 2015;34(11):1801\u201317. https:\/\/doi.org\/10.1002\/sim.6453.","journal-title":"Stat Med."},{"issue":"1","key":"6803_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12874-016-0110-x","volume":"16","author":"P Royston","year":"2016","unstructured":"Royston P, Parmar MK. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. BMC Med Res Methodol. 2016;16(1):16. https:\/\/doi.org\/10.1186\/s12874-016-0110-x.","journal-title":"BMC Med Res Methodol."},{"issue":"3","key":"6803_CR45","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1536867x1601600308","volume":"16","author":"TG Karrison","year":"2016","unstructured":"Karrison TG. Versatile tests for comparing survival curves based on weighted Log-rank statistics. Stata J. 2016;16(3):678\u201390. https:\/\/doi.org\/10.1177\/1536867x1601600308.","journal-title":"Stata J."},{"issue":"2","key":"6803_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1177\/1536867X1701700209","volume":"17","author":"P Royston","year":"2017","unstructured":"Royston P. A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome. Stata J. 2017;17(2):405\u201321. https:\/\/doi.org\/10.1177\/1536867X1701700209.","journal-title":"Stata J."},{"issue":"20","key":"6803_CR47","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/sim.8186","volume":"38","author":"D Magirr","year":"2019","unstructured":"Magirr D, Burman CF. Modestly weighted logrank tests. Stat Med. 2019;38(20):3782\u201390. https:\/\/doi.org\/10.1002\/sim.8186.","journal-title":"Stat Med."},{"issue":"1","key":"6803_CR48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12874-021-01372-0","volume":"21","author":"K Jachno","year":"2021","unstructured":"Jachno K, Heritier S, Wolfe R. Impact of a non-constant baseline hazard on detection of time-dependent treatment effects: a simulation study. BMC Med Res Methodol. 2021;21(1):177. https:\/\/doi.org\/10.1186\/s12874-021-01372-0.","journal-title":"BMC Med Res Methodol."},{"issue":"5","key":"6803_CR49","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/pst.2163","volume":"20","author":"R Temple","year":"2021","unstructured":"Temple R. Encouragement of subgroup assessment by the FDA. Pharm Stat. 2021;20(5):923\u20138. https:\/\/doi.org\/10.1002\/pst.2163.","journal-title":"Pharm Stat."},{"key":"6803_CR50","volume-title":"Causal Inference: What If","author":"MA Hern\u00e1n","year":"2020","unstructured":"Hern\u00e1n MA, Robins J. Causal inference: what if. Boca Raton: Chapman and Hall\/CRC; 2020."},{"issue":"4","key":"6803_CR51","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/19466315.2020.1755722","volume":"12","author":"JW Bartlett","year":"2020","unstructured":"Bartlett JW, Morris TP, Stensrud MJ, Daniel RM, Vansteelandt SK, Burman CF. The hazards of period specific and weighted hazard ratios. Stat Biopharm Res. 2020;12(4):518\u20139. https:\/\/doi.org\/10.1080\/19466315.2020.1755722.","journal-title":"Stat Biopharm Res."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06803-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06803-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T08:10:56Z","timestamp":1728115856000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06803-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6803"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06803-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"857"}}